))
DNA science. Artificial intelligence. Smartphones and 3D printers. Science and technology have transformed the world we live in. But how did we get here? It wasn’t by accident. Well, sometimes it was. It was also the result of hard work, teamwork, and competition. And incredibly surprising moments. Hosted by bestselling author Steven Johnson (“How We Got To Now”), American Innovations uses immersive scenes to tell the stories of the scientists, engineers, and ordinary people behind the great ...
AAO '22 Late-Breaking Talks: Gene Therapies for GA and XLRP
Manage episode 348574149 series 2134816
Зроблено Bryn Mawr Communications і знайдено завдяки Player FM та нашій спільноті. Авторські права належать видавцю, а не Player FM, і аудіоматеріали транслюються безпосередньо з сервера видавця. Натисніть на кнопку Підписатися, щоб слідкувати за оновленнями в Player FM або скопіюйте і вставте посилання на канал до іншої програми для подкастів.
We know about long-term intravitreal injections that might slow the progression of geographic atrophy (GA). But could a gene therapy in the pipeline require fewer treatments and still yield results? Jeffrey Heier, MD, summarized an AAO presentation on the phase 1 data of JNJ-1887 (Janssen), a potential gene therapy for GA. Was it safe—and were there signs of efficacy? Michel Michaelides, BSc, MB,, BS MD(Res), FRCOphth, joined us to speak about a gene therapy targeting x-linked retinitis pigmentosa. With a phase 3 study for the drug AAV5-RPGR (Jannsen/MeiraGTx) already underway, what can we learn from earlier trial results?
155 епізодів
